Psychopharmacology of borderline personality disorder.
Pharmacotherapy for patients with borderline personality disorder is directed against the psychobiology of cognitive-perceptual, affective, and impulsive-behavioral symptoms. A symptom-specific method using current empiric evidence for drug efficacy in each symptom domain is proposed. Drugs in each medication class have some potential utility against specific symptoms in patients with borderline personality disorder.
Soloff
P H
PH
Department of Psychiatry, University of Pittsburgh, Pennsylvania, USA.
D000465:Algorithms; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001883:Borderline Personality Disorder / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D016651:Lithium Carbonate / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D013577:Syndrome
D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D011619:Psychotropic Drugs; D016651:Lithium Carbonate